Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Inventory (2023 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Inventory for 3 consecutive years, with -$72000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Inventory fell 111.32% to -$72000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 38.32% increase, with the full-year FY2024 number at $2.1 million, up 222.44% from a year prior.
  • Change in Inventory was -$72000.0 for Q3 2025 at Gyre Therapeutics, down from $954000.0 in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $1.5 million in Q1 2025 to a low of -$921000.0 in Q3 2023.
  • A 3-year average of $255909.1 and a median of $118000.0 in 2024 define the central range for Change in Inventory.
  • Peak YoY movement for Change in Inventory: soared 714.53% in 2024, then crashed 111.32% in 2025.
  • Gyre Therapeutics' Change in Inventory stood at -$184000.0 in 2023, then surged by 164.13% to $118000.0 in 2024, then crashed by 161.02% to -$72000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Inventory are -$72000.0 (Q3 2025), $954000.0 (Q2 2025), and $1.5 million (Q1 2025).